Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of D3L-001 to treat advanced breast cancer. The people in this study have breast cancer that cannot be cured with standard therapies. Their tumors also make the HER2 protein, which plays a role in cancer growth.
The standard treatment for high-risk locally advanced cervical cancer is chemoradiation followed by maintenance therapy. Locally advanced means the cervical cancer has spread to nearby tissue or lymph nodes. In this study, researchers want to see if adding induction therapy before chemoradiation is more effective than standard therapy.
Atezolizumab and durvalumab are standard drugs used to treat small cell lung cancer (SCLC). Researchers want to see if adding iadademstat to standard treatment helps slow SCLC growth longer than standard immunotherapies alone. The people in this study have SCLC that spread outside the lung or to other parts of the body.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of CTIM-76 to treat advanced ovarian or endometrial cancer. The people in this study have ovarian or endometrial cancer that makes a protein called CLDN6. This protein may fuel cancer growth.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
This study is assessing ABBV-637 and ABBV-155 with ERAS-801 or standard treatment in people with glioblastoma. The people in this study have newly diagnosed glioblastoma or glioblastoma that returned after treatment and can be surgically removed. In addition, their tumors have a mutation (change) in the EGFR gene.
Researchers are assessing the effectiveness of the combination of lenvatinib, pembrolizumab immunotherapy, and fulvestrant to treat advanced breast cancer. The people in this study have inoperable or metastatic breast cancer (cancer that has spread) that is estrogen receptor-positive and HER2-negative.
Researchers want to see how well ivonescimab works as a treatment for endometrial and cervical cancers. The people in this study have endometrial or cervical cancer that keeps growing after treatment.
Researchers are assessing MEDI5752 and AZD2936 with standard treatments in people with cancer. The people in this study have primary liver or biliary cancer, including biliary tract or gallbladder cancer, that spread or cannot be surgically removed (inoperable). In addition, they have not yet received treatment for the cancer.
